NASDAQ$ALKS

Alkermes plc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Alkermes reported strong financial results driven by LYBALVI®, ARISTADA®, and VIVITROL® sales and reiterated financial expectations for 2022.

Alkermes plc reported first quarter 2022 financial results, with total revenues of $278.5 million compared to $251.4 million for the same period in the prior year. The company reported a GAAP loss per share of $0.22 and non-GAAP earnings per share of $0.12. They reiterated their financial expectations for 2022.

  • Total revenues for the quarter were $278.5 million, compared to $251.4 million for the same period in the prior year.
  • Net sales of proprietary products for the quarter were $171.3 million, compared to $130.0 million for the same period in the prior year.
  • GAAP net loss was $35.9 million for the quarter, or a basic and diluted GAAP loss per share of $0.22.
  • Non-GAAP net income was $19.6 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.12.

Headline financials

Total Revenue

$279M

Previous: $251M+10.8%
EPS (adj)

$0.12

Previous: $0.11+9.1%
Capital Expenditures

-$7.79M

Previous: -$7.99M+2.4%
Free Cash Flow

-$43.7M

Previous: -$30.4M-43.7%
Net Income

-$35.9M

Previous: -$22.4M-60.2%
Operating Income

-$26.6M

Previous: -$16.4M-61.8%
Gross Profit

$223M

Previous: $210M+6.2%
Cash & Equivalents

$283M

Previous: $205M+37.8%
Total Assets

$1.98B

Previous: $1.88B+5.3%
Stock-Based Comp

$18.3M

No prior period

Revenue & EPS history

Alkermes · Revenue · Quarterly

$279M

Q1 2022+10.8%vs Q1 2021
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Alkermes · $171M total across 3 segments · Q1 2022

  • VIVITROL
    $84.9M+14.0%
  • ARISTADA
    $72.5M+30.9%
  • LYBALVI
    $13.9M

Forward guidance

Alkermes reiterates its financial expectations for 2022, and the assumptions underlying such expectations, as set forth in its press release dated Feb. 16, 2022.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-0.6%

Avg return

Earnings day

-0.0%

Avg return

5 days after

-0.5%

Avg return

30 days after

45%

27 / 60 earnings

Positive

+16.6%

Q4 2017

Best reaction

-14.8%

Q1 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.2%+2.5%+27.0%
Q4 2025-6.6%-9.4%-12.0%
Q3 2025+3.9%+3.3%+0.0%
Q1 2025+6.3%+5.5%+6.4%
Q4 2024+4.8%+12.3%+6.5%
Q3 2024-6.3%-5.1%+3.3%
Q2 2024+12.2%+11.7%+11.8%
Q1 2024-2.8%-1.8%-4.6%
Q4 2023+15.0%+8.6%+2.7%
Q3 2023-2.4%-4.0%-3.7%
Q2 2023-1.8%-5.1%-11.9%
Q1 2023-7.1%-6.1%-3.9%
Q4 2022+4.0%+2.9%-3.6%
Q3 2022+3.8%+0.3%+12.2%
Q2 2022-9.7%-14.4%-16.5%
Q1 2022+9.8%+6.4%+12.5%
Q4 2021+8.8%+7.6%+12.1%
Q3 2021-8.2%-5.0%-28.7%
Q2 2021+5.9%+11.6%+28.9%
Q1 2021-3.2%-1.6%+0.8%
Q4 2020-11.8%-13.7%-15.3%
Q3 2020+5.6%+5.9%+20.2%
Q2 2020-8.8%-7.4%-19.0%
Q1 2020-14.8%-14.7%+1.6%
Q4 2019-7.0%-7.8%-15.5%
Q3 2019+5.7%+6.0%+13.9%
Q2 2019-10.2%+1.2%-12.3%
Q1 2019-12.2%-12.7%-31.1%
Q4 2018-1.2%+3.6%+3.3%
Q3 2018+3.0%+6.5%-11.6%
Q2 2018-0.1%-0.3%+2.0%
Q1 2018+1.5%+1.4%+3.9%
Q4 2017+16.6%+23.0%+12.0%
Q3 2017+0.7%-1.5%+3.2%
Q2 2017-4.1%-5.4%-12.4%
Q1 2017+2.0%+2.4%+1.0%
Q4 2016-2.9%-4.6%+3.7%
Q3 2016-1.4%+4.0%+8.4%
Q2 2016-3.6%-6.0%-14.1%
Q1 2016-2.0%
Q4 2015-1.4%
Q3 2015+7.6%
Q2 2015+2.4%
Q1 2015+3.1%
Q4 2014-3.4%
Q3 2014+7.7%
Q2 2014-7.2%
Q1 2014+3.2%
Q4 2013-7.7%
Q3 2013-3.7%
Q2 2013+3.5%
Q1 2013+3.9%
Q4 2010-1.0%
Q4 2012-9.9%
Q3 2012+2.2%
Q3 2011+2.2%
Q2 2011-7.7%
Q2 2012-7.7%
Q4 2011-7.7%
Q2 2010-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro